Dupilumab (DUP) is a monoclonal antibody that inhibits interleukin IL-4 and IL-13 signaling and is approved for type 2 Inflammatory Disease such as asthma, chronic rhinosinusitis with nasal polyposis and atopic dermatitis. This evidence concerns the gene IL13 and chronic rhinosinusitis.